Short term safety and tolerability of a fixed dose combination of olmesartan, amlodipine and hydrochlorothiazide

Journal of Clinical and Diagnostic Research

Volumn 9, Issue 8, 2015, Pages OC10-OC13

  Mohan, J C ^a   Jain, Rishi ^b   Chamle, Vijay ^b   Bhargava, Amit ^b  

^a FORTIS HOSPITAL   (India)

^b Glenmark Pharmaceuticals Limited   (India)

Author keywords

Adverse event; Hypertension; Observational; Prescription event monitoring

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OLMESARTAN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FATIGUE; FEMALE; FOOT EDEMA; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONITORING; OBSERVATIONAL STUDY; PRESCRIPTION EVENT MONITORING;

EID: 84938575612     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2015/14054.6366     Document Type: Article

References (17)

1. Jicheng LV, Neal B, Ehteshami P, Ninomiya T, Woodward M, Rodgers A, et al. Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis. PLoS Med. 2012;9(8):e1001293. doi:10.1371/journal.pmed.1001293
2. Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013;347:f5680. doi:10.1136/bmj.f5680
3. Barrios V, Escobar C, Echarri R. Fixed combinations in the management of hypertension: perspectives on lercanidipine – enalapril. Vasc Health Risk Manag. 2008;4(4):847–53.
4. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am SocHypertens. 2010;4:42–50.
5. Gradman AH. Rationale for Triple-Combination Therapy for Management of High Blood Pressure. The Journal of Clinical Hypertension. 2010;12(11):869–78.
6. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. ClinTher. 2010;32:1252-69.
7. Mann RD. Prescription-event monitoring—recent progress and future horizons. Br J ClinPharmacol. 1998;46(3):195–201.
8. Nayak G, Harsha KP, Jayanthi CR, Bhat S, Patil U, Narendra J, et al. Efficacy of triple combination olmesartan 20 mg amlodipine 5 mg hydrochlorthiazide 12.5 mg (OAH) vs dual combination of olmesartan 20 mg amlodipine 5 mg (OA) in patients with hypertension, a double blind, randomized, comparative study. International Journal of Cardiology. 2011;152:S84.
9. Kereiakes DJ, Chrysant SG, IzzoJr JL, Littlejohn T, Melino M, Lee J, et al. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovascular Diabetology. 2012;11:134. doi:10.1186/1475-2840-11-134
10. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20.
11. Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) [Highlights of Prescribing Information] Daiichi Sankyo, Inc.; Revised: 09/2012 [cited 2015 Mar 17]]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/200175s011lbl.pdf
12. Kreutz R. Olmesartan/amlodipine: a review of its use in the management of hypertension. Vasc Health Risk Manag. 2011;7:183–92.
13. NORVASC (amlodipine besylate) [Highlights of Prescribing Information] Pfizer Labs; Revised: May 2011 [cited 2015 Mar 17]]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s047lbl.pdf
14. Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, et al. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. N Engl J Med. 2011;364:907-17.
15. Imai E, Chan JCN, Ito S, Yamasaki T, Kobayashi F, Haneda M, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomized, placebo-controlled study. Diabetologia. 2011;54:2978–86.
16. FDA Drug Safety Communication: FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive; label updates required. [Internet]. 2014 June 24 [cited 2015 Mar 17]; Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM402339.pdf
17. Dyazide (hydrochlorothiazide/triamterene) [Prescribing Information] Glaxo SmithKline; October 2009 [cited 2015 Mar 17]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/016042s077lbl.pdf